MarketBeat Week in Review – 01/26

Equity markets closed a volatile week after the announcement of the next Federal Reserve chair and a hotter-than-expected December inflation print, which pressured gold and silver and added to cross-asset volatility. Big-tech earnings have been generally solid but fell short of aggressive expectations—particularly on AI monetization—while major averages finished January up over 1%; COVID of sector- and company-specific drivers (proposed Medicare reimbursement cuts hitting UnitedHealth, Greenland-related tariff talk affecting rare-earths, uranium and chip-equipment interest, expanded share-buyback activity, and mixed guidance from large-cap tech) should steer near-term rotation and trading opportunities.

Analysis

Market structure: The week’s data and Fed-chair noise favor durable-growth providers of AI infrastructure (chip-equipment, power/energy) and issuers that can monetize buybacks; losers include health insurers (UNH) and commodity safe-havens (gold/silver) on a hot CPI print. Expect a rotation: multiple compression on long-duration growth if 10y yields move +30–50bps; cyclical capex beneficiaries (LRCX/AMAT) gain if AI spend guidance holds.

Risk assessment: Tail risks include a hawkish Fed appointment that pushes 10y >4% within 3–6 months (sharp tech drawdown), tariff escalation hitting rare-earth imports, or CMS finalizing deeper Medicare cuts to insurers. Near-term (days-weeks) volatility will center on earnings and Fed commentary; medium-term (3–12 months) depends on persistent CPI trajectory and corporate buyback flows; long-term (1–3 years) is driven by AI capex trajectory and energy transition adoption.

Trade implications: Tactical longs into earnings: selective semicap and renewable names, small defined-risk option exposure to oversold tech (QCOM) and RKLB on event-driven sell-offs; hedge insurer exposure (UNH) with cheap put spreads. Rotate 3–6% from defensive staples into capex/energy names if CPI normalizes but keep cash to buy on 10–15% broad-market pullbacks.

Contrarian angles: Consensus fears over AI monetization may be overstated—capital budgets lag revenue recognition: better to play equipment suppliers (LRCX/AMAT) and energy base-layer names rather than headline tech (MSFT) where multiple is priced for perfection. Conversely, Medicare-driven insurer sell-offs could be overdone given institutional support; a measured re-entry on policy clarity could deliver 10–20% rebounds over 3–9 months.

Key Decisions for Investors

• Establish a 2% long position in Qualcomm (QCOM) ahead of earnings; add to 4% if shares drop 8–12% post-report. Complement with a defined-risk options sleeve: buy 3-month 10% OTM calls sized at 0.5% of portfolio risk, take profits at +100% or cut at -100% of premium.
• Initiate a tactical hedge against US health insurers: buy a 3-month UNH put spread (5%/15% OTM) allocating 0.5–1% of portfolio to protect sector exposure. If CMS final rule reduces reimbursements further, increase hedge to 2% net exposure or convert to outright short.
• Allocate 3% across semiconductor-equipment names LRCX and AMAT (1.5% each) as a medium-term AI-capex play; target +25% in 6–12 months. Add incrementally on any >15% drawdown and trim 30% on a >25% run-up.
• Buy 1% position in BlackRock (BLK) to capture secular ETF/inflow tailwinds; set a 15% stop-loss and reassess after two quarterly AUM updates or if monthly ETF net flows exceed +$5B, at which point consider adding to 2% and selling covered calls to harvest yield.